Hyperion Therapeutics (HPTX) Tops Q3 EPS by 18c, Maintains FY Revenue Guidance

Hyperion Therapeutics (NASDAQ: HPTX) reported Q3 EPS of $0.05, $0.18 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $26.2 million versus the consensus estimate of $24.6 million.

2014 Financial Guidance Update

Hyperion reiterates its 2014 revenue guidance and continues to anticipate total net revenues to be in the range of $105 to $110 million. The company anticipates total net revenues for RAVICTI to range from $89 to $93 million and BUPHENYL net revenues to range from $16 to $17 million. The company is revising its adjusted 2014 operating expense, R&D and SG&A guidance downward, from the previously issued guidance of $66 to $78 million and now anticipate it to be in the range of $64 to $70 million which excludes amortization expense, stock-based compensation expense, and impairment charges related to the Andromeda acquisition. The company continues to expect amortization expense and stock-based compensation expense to be approximately $4 million to $5 million and $7.5 million to $8.5 million respectively

For earnings history and earnings-related data on Hyperion Therapeutics (HPTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Diana Shipping withdraws bid to acquire Genco Shipping